Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Treasury Shares (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed Treasury Shares for 6 consecutive years, with $323.3 million as the latest value for Q4 2025.

  • Quarterly Treasury Shares rose 17.55% to $323.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $323.3 million through Dec 2025, up 17.55% year-over-year, with the annual reading at $323.3 million for FY2025, 17.55% up from the prior year.
  • Treasury Shares hit $7.6 million in Q4 2025 for BridgeBio Pharma, roughly flat from $7.6 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $10.9 million in Q1 2023 to a low of -$3.8 million in Q4 2021.
  • Historically, Treasury Shares has averaged $5.4 million across 5 years, with a median of $6.2 million in 2022.
  • Biggest five-year swings in Treasury Shares: skyrocketed 266.67% in 2021 and later changed 0.0% in 2022.
  • Year by year, Treasury Shares stood at $275.0 million in 2021, then changed by 0.0% to $275.0 million in 2022, then changed by 0.0% to $275.0 million in 2023, then changed by 0.0% to $275.0 million in 2024, then grew by 17.55% to $323.3 million in 2025.
  • Business Quant data shows Treasury Shares for BBIO at $323.3 million in Q4 2025, $323.3 million in Q3 2025, and $323.3 million in Q2 2025.